Back to top
more

AC Immune (ACIU)

(Delayed Data from NSDQ)

$3.91 USD

3.91
218,113

0.00 (0.00%)

Updated Jul 26, 2024 04:00 PM ET

Pre-Market: $3.99 +0.08 (2.05%) 9:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

by Zacks Equity Research

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen (BIIB) Seeks Approval for Another Alzheimer's Candidate

by Zacks Equity Research

Biogen (BIIB) and partner Eisai start rolling submission of a regulatory filing seeking approval for lecanemab (BAN2401) as a potential approval for early Alzheimer's disease.

AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study

by Zacks Equity Research

AC Immune's (ACIU) candidate for mild-to-moderate AD meets one of the two co-primary endpoints. Resultantly, the stock price rises 16%

Biotech Stock Roundup: REGN Gives Study Update, INCY Wins Drug Approval & More

by Zacks Equity Research

Regulatory and pipeline updates from Regeneron (REGN) and Incyte (INCY), among others, have been in focus in the biotech industry over the past week.

AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of -31.82% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AC Immune (ACIU) Q2 Earnings Expected to Decline

by Zacks Equity Research

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AC Immune (ACIU) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of -19.05% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Biotech Stock Roundup: REGN's Drug Approval & Pipeline Updates From AMGN, BLUE

by Zacks Equity Research

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Amgen (AMGN) and bluebird (BLUE).

AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of -16.67% and 32.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

by Zacks Equity Research

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AC Immune's Candidate Fails in Alzheimer's Disease Study

by Zacks Equity Research

The failure of AC Immune's (ACIU) study on Alzheimer's disease brings this challenging but promising space in focus.

Do Options Traders Know Something About AC Immune (ACIU) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to AC Immune (ACIU) stock based on the movements in the options market lately.

Amicus' (FOLD) Q2 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Amicus (FOLD) posts a narrower-than-expected loss, while sales beat estimates in the second quarter of 2020.

Aerie (AERI) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.

AMAG Pharmaceuticals' (AMAG) Q2 Loss Narrower Than Expected

by Zacks Equity Research

AMAG (AMAG) posts a narrower-than-expected loss and revenues miss estimates in the second quarter of 2020.

All You Need to Know About AC Immune (ACIU) Rating Upgrade to Strong Buy

by Zacks Equity Research

AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Horizon (HZNP) Q2 Earnings Down Y/Y, Tepezza Drives Sales

by Zacks Equity Research

Horizon Therapeutics' (HZNP) earnings decline year over year and sales beat estimates in the second quarter of 2020.

Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis (ZTS) beats both earnings and sales estimates in the second quarter of 2020.

AC Immune (ACIU) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of 25.00% and 215.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

AC Immune Advances Alzheimer's Vaccine to Phase Ib/IIa Study

by Zacks Equity Research

AC Immune (ACIU) advances its Alzheimer's disease vaccine, ACI-35.030, to phase Ib/IIa study.

AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of 47.06% and 24.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Company News for Mar 24, 2020

by Zacks Equity Research

Companies in the news are: HAS, PCG, WTRH, ACIU

Moderna (MRNA) Catches Eye: Stock Jumps 6.4%

by Zacks Equity Research

Moderna (MRNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Guardant Health (GH) in Focus: Stock Moves 6.5% Higher

by Zacks Equity Research

Guardant Health (GH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.